$170.38
1.81% yesterday
Nasdaq, Oct 06, 10:00 pm CET
ISIN
US6323071042
Symbol
NTRA

Natera, Inc. Stock price

$170.38
+2.99 1.79% 1M
+32.12 23.23% 6M
+12.08 7.63% YTD
+42.18 32.90% 1Y
+123.35 262.28% 3Y
+98.97 138.59% 5Y
+161.05 1,726.15% 10Y
+147.64 649.25% 20Y
Nasdaq, Closing price Mon, Oct 06 2025
+3.03 1.81%
ISIN
US6323071042
Symbol
NTRA
Industry

Key metrics

Basic
Market capitalization
$23.0b
Enterprise Value
$22.0b
Net debt
positive
Cash
$1.0b
Shares outstanding
136.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.7 | 10.9
EV/Sales
11.2 | 10.4
EV/FCF
210.7
P/B
18.4
Financial Health
Equity Ratio
72.0%
Return on Equity
-15.9%
ROCE
-21.4%
ROIC
-43.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$2.0b | $2.1b
EBITDA
$-258.5m | $-270.1m
EBIT
$-293.6m | $-320.0m
Net Income
$-253.2m | $-270.0m
Free Cash Flow
$104.6m
Growth (TTM | estimate)
Revenue
44.4% | 24.3%
EBITDA
9.2% | -41.2%
EBIT
6.4% | -44.0%
Net Income
13.3% | -41.8%
Free Cash Flow
188.8%
Margin (TTM | estimate)
Gross
62.9%
EBITDA
-13.2% | -12.8%
EBIT
-15.0%
Net
-12.9% | -12.8%
Free Cash Flow
5.3%
More
EPS
$-1.9
FCF per Share
$0.8
Short interest
2.9%
Employees
4k
Rev per Employee
$380.0k
Show more

Is Natera, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Natera, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Natera, Inc. forecast:

25x Buy
89%
2x Hold
7%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Natera, Inc. forecast:

Buy
89%
Hold
7%
Sell
4%

Financial data from Natera, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,964 1,964
44% 44%
100%
- Direct Costs 730 730
16% 16%
37%
1,235 1,235
69% 69%
63%
- Selling and Administrative Expenses 1,026 1,026
45% 45%
52%
- Research and Development Expense 502 502
49% 49%
26%
-259 -259
9% 9%
-13%
- Depreciation and Amortization 35 35
22% 22%
2%
EBIT (Operating Income) EBIT -294 -294
6% 6%
-15%
Net Profit -253 -253
13% 13%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Natera, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Natera, Inc. Stock News

Neutral
Business Wire
6 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients. Initiated in 2023, EXPAND is designed to be the defining prospective clinical trial in the category, supporting Natera's Fetal Focus™ single gene noninvasive prenatal test...
Neutral
Business Wire
7 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for patients with germ ...
Neutral
Business Wire
8 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the most common gynecol...
More Natera, Inc. News

Company Profile

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.

Head office United States
CEO Stephen Chapman
Employees 4,429
Founded 2004
Website www.natera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today